NCT00466245View on ClinicalTrials.gov

Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

590

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Smallpox
Interventions
DRUG

MVA Smallpox vaccine

Two 0.5mL subcutaneous injections, separated by 28 days

DRUG

Placebo

Two 0.5mL subcutaneous injections, separated by 28 days

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00466245 - Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine | Biotech Hunter | Biotech Hunter